medroxyprogesterone injection / Generic mfg. - LARVOL DELTA

Plasmid-encoded Pgp3 protein enhances the infectivity of Chlamydia trachomatis serovar L2 in mice. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "Pgp3 rather than Pgp4, other plasmid-encoded genes, or the plasmid-regulated GlgA gene, plays a critical role in the infectivity of C. trachomatis serovar L2 in mice. In addition, even very low levels of Pgp3 expression may be sufficient to maintain L2 infectivity in mice."

Journal • Preclinical • Infectious Disease • Infertility • Ophthalmology • Sexual Disorders • Vaginitis

Recall and understanding of HIV-related counseling messages among progestin implant and injectable contraception users in Malawi. (PubMed, AIDS Care) - "We conducted a randomized clinical trial among Malawian women with and without HIV who were initiating the levonorgestrel (LNG) implant or depot medroxyprogesterone acetate (DMPA) injectable...In contrast, women more frequently recalled messages about potential reduced contraceptive effectiveness of the implant when used with ART. Women who continued their assigned contraceptive method were more likely to accurately recall counseling messages.Improved counseling strategies are needed to support clear communication and understanding of complex and evolving contraceptive and HIV-related risk information."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives

Risk of ischemic and hemorrhagic stroke in users of progestogen-only contraceptives: A Danish registry study. (PubMed, Contraception) - "POCs-including POPs, implants, injections, and LNG-IUDs-were not associated with an increased risk of either IS or ICH and support their use as appropriate alternatives to CHCs with ethinylestradiol for women in whom stroke risk is an important clinical consideration."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke • Long-acting Reversible Contraceptives

Anaphylactic Induction of Lupus Nephritis and Posterior Reversible Encephalopathy Syndrome Following Administration of Depo-Provera. (PubMed, Case Reports Immunol) - "Treatment included pulse corticosteroids, seizure prophylaxis, immunosuppressants, and antihypertensive therapy, resulting in neurological and renal recovery. Although causality cannot be inferred, the temporal sequence raises the hypothesis that immune activation associated with DMPA exposure, or hypersensitivity to one of its excipients, may have contributed to the clinical unmasking of autoimmune disease."

Journal • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

An exploratory analysis of the association between progesterone use and tumor-related visual deficit in women with meningioma. (PubMed, Int J Radiat Oncol Biol Phys) - "Progesterone use was associated with meningioma-related visual deficit in women referred for radiotherapy. Providers should be aware of this potential risk factor and further study is warranted."

Journal • Brain Cancer • Genetic Disorders • Meningioma • Neurofibromatosis • Oncology • Solid Tumor • PGR

Prevalence and associated risk factors of uterine fibroids in the Kingdom of Eswatini. (PubMed, S Afr Fam Pract (2004)) - " Uterine fibroids are highly prevalent and significantly associated with age, underscoring the need for targeted awareness and future research.Contribution: The study provided insights to inform policy and enhance preventive strategies within the sexual reproductive health programs."

Journal • Diabetes • Genetic Disorders • Gynecology • Metabolic Disorders • Obesity • Solid Tumor • Uterine Leiomyoma • Women's Health

Contraceptive practices during monitoring for molar pregnancy: A mixed methods analysis. (PubMed, Contraception) - "One-fifth of patients did not use contraception during molar pregnancy monitoring, highlighting an opportunity for improved contraceptive counseling and alignment with guidelines to reduce the risk of unintended pregnancy and avoid potential confounding of malignant transformation."

Journal • Gestational Trophoblastic Neoplasia

Mechanistic understanding of LAI suspension intramuscular depot formation: A physicochemical perspective. (PubMed, J Control Release) - "The present study provides a mechanistic understanding of intramuscular depot formation and drug release of Depo-Provera® (medroxyprogesterone acetate) injectable suspension and its qualitatively and quantitatively (Q1/Q2) equivalent formulations from a physicochemical perspective...Co-administration of dexamethasone microspheres markedly attenuated inflammation and reduced CD68-positive cell density across the formulations. However, no clear correlation was observed between particle size and in vivo drug release under the study conditions, potentially due to confounding factors affecting systemic clearance. Instead, a potential association was identified between depot structure, local immune response, and drug release kinetics, highlighting depot morphology and tissue interactions as key determinants of the in vivo performance."

Journal • Inflammation • CD68

Previous Cerebral Venous Sinus Thrombosis in Pregnancy: Clinical Challenges and Outcomes - A Case Report. (PubMed, Int J Womens Health) - "She had a history of depot medroxyprogesterone acetate (DMPA) injections prescribed by healthcare providers and combined injectable contraception used on her own initiative after being diagnosed with CVST. During pregnancy, anticoagulation management was suboptimal because warfarin therapy was continued until pregnancy was recognized and subsequently discontinued by the patient...This case highlights the importance of appropriate contraceptive counseling in women with a history of CVST and the need for pregnancy-safe anticoagulation strategies to minimize thrombotic complications and optimize maternal and fetal outcomes. Management of CVST in pregnancy should involve a multidisciplinary team to determine the safest mode of delivery and optimize maternal and fetal outcomes."

Journal • Cardiovascular • Hematological Disorders • Long-acting Reversible Contraceptives • Pain • Thrombosis

A phase 1, randomized, open-label, single-dose relative bioavailability study of upper arm injection of depot medroxyprogesterone acetate comparing pharmacokinetics and hormone indicators of ovulation with anterior thigh and abdomen injection. (PubMed, Contraception) - "This study shows upper arm injection of DMPA-SC (104 mg) should have safety and effectiveness comparable to injection at the currently approved sites (anterior thigh, abdomen), based on MPA PK parameters and hormonal markers of ovulation and could be an acceptable option for women using this form of injectable contraception."

Journal • P1 data • PK/PD data • Long-acting Reversible Contraceptives

Contraceptive Progestogens and Incident Meningioma. (PubMed, JAMA Netw Open) - "For combined oral contraceptives, the estimated odds ratios (ORs) for the association between use of progestogens and meningioma were 1.61 (95% CI, 1.00-2.59) with cyproterone, 1.66 (95% CI, 1.31-2.10) with desogestrel, 1.58 (95% CI, 1.05-2.37) with drospirenone, 1.44 (95% CI, 1.17-1.77) with gestodene, 1.40 (95% CI, 1.12-1.76) with levonorgestrel, 1.38 (95% CI, 0.77-2.47) with norethisterone, and 1.04 (95% CI, 0.70-1.54) with norgestimate. In this case-control study conducted using data from the entire Danish population, recent use of the contraceptive progestogens cyproterone, desogestrel, drospirenone, gestodene, levonorgestrel, injectable medroxyprogesterone, and high-dose IUD was associated with increased risk of meningioma. These findings are considered relevant information for the treated women and the prescribing physicians."

Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Contraception Use and Patterns in Liver Compared to Kidney Transplant Recipients: An Analysis Using Real World Data (ATC 2026) - "Contraceptive exposures included progestin-only pills (POPs), combined hormonal contraceptives (CHCs), medroxyprogesterone injections (Depot), etonogestrel implants, hormonal intrauterine devices (IUDs), copper IUDs (Cu-IUD), and emergency contraception (EC). Only one in four reproductive-aged female SOT recipients received contraception. Progestin-based methods dominated initial therapy selection and demonstrated the greatest stability, with significantly fewer switches than CHCs, though medroxyprogesterone use was notably higher than expected. These findings demonstrate an opportunity to improve proactive, transplant-specific contraceptive care pathways."

Clinical • Real-world • Real-world evidence • Gynecology • Long-acting Reversible Contraceptives • Solid Organ Transplantation • Transplantation

Collective loss of type 17 cytokines leads to estrogen-independent susceptibility to vulvovaginal candidiasis (ASRI 2026) - "However, our emerging data reconciles this paradox by revealing that the combinatorial actions of IL-17 and IL-22 are required to limit vaginal fungal infection.Method of Study: Female mice were given estradiol (0.1 mg subcutaneously) or sesame oil vehicle on days -3 and 4 relative to infection or depot medroxyprogesterone acetate (Depo-Provera, 2 mg subcutaneously) or saline vehicle on days -5 and 2 relative to infection... We discovered that the combined actions of IL-17 and IL-22 signaling limit fungal infection in the vaginal tract. Our work suggests that there are two independent pathways that drive susceptibility of murine VVC: loss of type 17 cytokine signaling or estradiol preconditioning. This work helps address the substantial gap of knowledge regarding host factors required for protective immune responses against VVC and reveals novel cooperativity of the IL-17/IL-22 signaling pathways in the female reproductive tract."

Candidiasis • Infectious Disease • Inflammation • Vaginitis • IL17A • IL17RA • IL1B • IL22

Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma. (PubMed, Neuro Oncol) - "Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera...The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma."

Clinical data • Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use: Systematic Review of Synthetic Progestins and Case Series of DMPA-Associated Intracranial Meningiomas. (PubMed, Neurosurgery) - "Long-term DMPA use is associated with a distinct pattern of multiple, bone-invasive, PR-positive meningiomas. Based on established patterns with other progestins, drug discontinuation and observation before surgical intervention should be considered for asymptomatic lesions, although prospective validation is warranted."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor • PGR

A Comparative Evaluation of Cut 380A Intrauterine Device Versus Depot Medroxyprogesterone Acetate For Long-Acting Reversible Contraception. (PubMed, J Pharm Bioallied Sci) - "Both LARCs were safe and highly effective; however, CuT 380A demonstrated superior 12-month continuation and satisfaction, whereas DMPA exhibited a higher drop-out largely driven by bleeding changes and desire for pregnancy. High-quality counselling on anticipated bleeding patterns could further optimize DMPA continuation."

Journal • Gynecology • Long-acting Reversible Contraceptives

Kuwa Free! - Live Free! (clinicaltrials.gov) - P=N/A | N=700 | Recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Quick Start of Highly Effective Contraception (clinicaltrials.gov) - P=N/A | N=270 | Completed | Sponsor: University of Utah | Active, not recruiting ➔ Completed | N=1030 ➔ 270

Enrollment change • Trial completion • Long-acting Reversible Contraceptives

Bladder Endometriosis Resolved by Robotic-Assisted Partial Cystectomy. (PubMed, Cureus) - "The patient failed medical management with Depo-Provera and GnRH antagonists and desired to proceed with surgical intervention...This case demonstrates that deep infiltrating bladder endometriosis should be on the differential for patients presenting with cyclic pelvic pain and urinary symptoms. Medical management is a reasonable first step depending on imaging findings, symptoms, and fertility goals; but surgical management with partial cystectomy may be warranted."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Urology • Women's Health

Idiopathic Intracranial Hypertension Prevalence and Hormonal Contraception: A Meta-Analysis. (PubMed, Neurology) - "The meta-analysis found no significant association between HC use and IIH prevalence, with consistent results across various HC modalities. This evidence provides confidence to reassure patients with IIH and clinicians that the directed use of HC should be continued as appropriate. The limited quality of available evidence and considerable heterogeneity highlights the necessity for large-scale, well-designed studies, particularly in diverse patient populations, to validate these findings."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Hypertension • Long-acting Reversible Contraceptives • Women's Health

FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov) - P2/3 | N=260 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

dMMR • Enrollment open • MSI-H • Tumor mutational burden • Endometrial Cancer • Oncology • Solid Tumor • ER • MSI • PD-L1 • POLE

Assessment of the risk of venous thromboembolism of combined hormonal contraceptives or progestin-only contraceptives in women over 18 in comparison with non-users or any other contraceptive (ISGE 2026) - "In contrast, progestin-only combinations had risks similar to non-use and were not statistically different, except for the medroxyprogesterone acetate injectable formulation, which showed an increased risk... A total of 85 studies were identified through abstract and full-text screening. Overall, 12 cohort and 17 case-control studies were included in the main quantitative analysis. Unadjusted analyses showed that, compared with non-use, all ethinyl estradiol-based combinations were associated with a significantly higher risk of VTE, with ethinyl estradiol/desogestrel showing the greatest excess risk."

Clinical • Cardiovascular • Hematological Disorders • Venous Thromboembolism

Addressing Unintended Teen Pregnancy Through Reproductive Health Service Delivery by School Nurses and Physicians. (PubMed, J Sch Health) - "By supporting access to reproductive health care, CATCH contributed to contraceptive uptake and reduced pregnancies among NYC teens."

Journal • Long-acting Reversible Contraceptives

School-Based Health Centers and Use of Effective Contraception among Sexually Active Female Teens in NYC Public High Schools. (PubMed, J Urban Health) - "SBHC RHP access significantly increased the probability of primary use of moderately effective hormonal contraception (pill/patch/ring/Depo-Provera shot) and LARC at last sex by 12.9 and 1.9 percentage points, respectively. While these more effective methods are generally less accessible to teens, the provision of these methods within an SBHC setting can increase access and use."

Journal • Long-acting Reversible Contraceptives

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (clinicaltrials.gov) - P4 | N=263 | Completed | Sponsor: Northwestern University | Recruiting ➔ Completed | N=653 ➔ 263

Enrollment change • Trial completion